Skip to Content

Roeland GW Verhaak, PhD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Genomic Medicine, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Office Address

The University of Texas MD Anderson Cancer Center
1881 East Road
Unit Number: 1958
Houston, TX 77054
Room Number: 3SCR6.4111
Phone: 713-563-2293
Fax: 713-563-4242

Education & Training

Degree-Granting Education

2006 Erasmus University Medical Center, Rotterdam, Netherlands, PHD, Medicine
2000 Radboud University, Nijmegen, Netherlands, MSc, Biomedical Science and Computer Science

Postgraduate Training

3/2007-1/2010 Research Fellowship, Broad Institute of Harvard and MIT, Cambridge, MA, Matthew Meyerson


Academic Appointments

Computational Biologist, The Broad Institute of MIT and Harvard, Cambridge, MA, 2/2010-9/2010
Research Scientist, Hematology, Erasmus Medical Center, Rotterdam, Netherlands, 6/2006-1/2007
Visiting Scientist, Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA, 3/2006-5/2006

Other Appointments/Responsibilities

Software Engineer, Dalicon BV, Nijmegen, Netherlands, 4/2002-3/2003

Honors and Awards

2015-present Robert M. Chamberlain Distinguished Mentor Award, MD Anderson Postdoctoral Association
2014 2014 Society for Neuro-Oncology Adult Basic Science Award
2013 Peter Steck Memorial Award, Pediatric Brain Tumor Foundation
2011 Wilson S. Stone Memorial Award, UT MD Anderson Cancer Center's Symposia on Cancer Research 2011
2008-2010 Fundamental and pre-clinical fellowship, Dutch Cancer Society KWF
2006 Netherlands Genomics Initiative Fellowship

Selected Publications

Peer-Reviewed Original Research Articles

1. Colen R, Foster I, Gatenby R, Giger ME, Gillies R, Gutman D, Heller M, Jain R, Madabhushi A, Madhavan S, Napel S, Rao A, Saltz J, Tatum J, Verhaak R, Whitman G. NCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics Signatures. Transl Oncol 7(5):556-69, 10/2014. e-Pub 10/24/2014. PMCID: PMC4225695.
2. Torres-GarcÝa W, Zheng S, Sivachenko A, Vegesna R, Wang Q, Yao R, Berger MF, Weinstein JN, Getz G, Verhaak RG. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics 30(15):2224-6, 8/2014. e-Pub 4/2014. PMCID: PMC4103589.
3. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315-22, 3/2014. e-Pub 1/2014. PMID: 24476821.
4. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell 155(2):462-77, 10/10/2013. PMCID: PMC3910500.
5. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, Cancer Genome Atlas (TCGA) Research Network, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG. Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 123(9):3740-50, 9/3/2013. e-Pub 8/15/2013. PMCID: PMC3754259.
6. Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WK, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, Verhaak RG. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev 27(13):1462-72, 7/1/2013. e-Pub 6/24/2013. PMCID: PMC3713427.
7. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, K÷bel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M, Cancer Genome Atlas Research Network. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123(1):517-25, 1/2/2013. e-Pub 12/21/2012. PMCID: PMC3533304.
8. Cancer Genome Atlas Research Network. Integrated Genomic Analyses of Ovarian Carcinoma. Nature 474(7353):609-15, 6/30/2011. e-Pub 6/29/2011. PMCID: PMC3163504.
9. Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks T. Suppression of Lung adenocarcinoma progression by Nkx2-1. Nature 473(7345):101-4, 5/5/2011. e-Pub 4/6/2011. PMCID: PMC3088778.
10. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98-110, 1/19/2010. PMCID: PMC2818769.
11. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, L÷wenberg B, Delwel R, Valk PJ. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94(1):131-4, 1/2009. e-Pub 10/6/2008. PMCID: PMC2625407.
12. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-8, 10/23/2008. e-Pub 9/4/2008. PMCID: PMC2671642.
13. Erkeland SJ, Verhaak RG, Valk PJ, Delwel R, L÷wenberg B, Touw IP. Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia. Cancer Res 66(2):622-6, 1/2006. PMID: 16423987.
14. Verhaak RG, Sanders MA, Bijl MA, Delwel R, Horsman S, Moorhouse MJ, van der Spek PJ, L÷wenberg B, Valk PJ. HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristics. BMC Bioinformatics 7:337, 2006. PMCID: PMC1574351.
15. Verhaak RG, Staal FJ, Valk PJ, Lowenberg B, Reinders MJ, de Ridder D. The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies. BMC Bioinformatics 7:105, 2006. PMCID: PMC1481623.
16. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, L÷wenberg B, Valk PJ. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106(12):3747-54, 12/2005. e-Pub 8/2005. PMID: 16109776.
17. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, L÷wenberg B, Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350(16):1617-28, 4/2004. PMID: 15084694.

Grant & Contract Support

Title: (PQ #4) Single cell barcoding for studies of study clonal evolution in glioblastoma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2014 - 8/31/2018
Title: Optimizing therapy for glioblastoma through genomic profiling of treatment failure
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 8/31/2014 - 8/30/2017
Title: SPORE in Brain Cancer
Funding Source: NIH/NCI
Role: Core Director, Biostatistics and Bioinformatics Core
Principal Investigator: Lang, Frederick
Duration: 9/17/2013 - 8/31/2018
Title: SPORE in Brain Cancer
Funding Source: NIH/NCI
Role: Project Leader, Project 2 (Targeting the PI3K Pathway in Malignant Glioma)
Principal Investigator: Lang, Frederick
Duration: 9/17/2013 - 8/31/2018
Title: Brain Tumor Therapeutic Efficacy by Quantitative Magnetic Resonance
Funding Source: NIH/NCI Sub Contract from the University of Michigan
Role: Core Leader
Principal Investigator: Brian Ross
Duration: 7/1/2013 - 6/30/2018
Title: An Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: John N. Weinstein
Duration: 9/29/2009 - 7/31/2015

Last updated: 1/27/2015